Hypi, your cynicism is understandable, but I think it fails to correctly factor in the financial incentives.
The idea of a BP crushing a Phase II trial of a microbiotech to protect their own franchises doesn't make sense. First, the odds of a huge success in this indication were not very clear based on the earlier trials. Even if Bavi did succeed, it is just a Phase II trial in one oncology indication. How could a success in such a trial threaten their current products until some years in the future?
Second, if Bavi was such a world beater, why wouldn't a BP just open the checkbook and buy Peregrine. They can do the math; they would know they could make a ton of money on such a product.
Third, why risk getting caught and face a legal, public relations and financial nightmare over an unproven, cheaply acquirable therapy. From a cost benefit point of view, their only point of view, it just doesn't make sense.
I'm just saying a better mouse trap that will make even more money than you are currently earning will get bought, not buried.
GLTA, Paul
Market Data 
Markets 
AI
